NASDAQ:IRON 17 October 2025 - 1 January 2026

Disc Medicine (NASDAQ: IRON) shares fell about 10% to $81 in heavy trading Friday, after a series of insider sales by executives and directors appeared in SEC filings. The drop comes ahead of an expected FDA decision on bitopertin for EPP. CEO John Quisel, director Kevin Bitterman, and William Savage all disclosed recent stock sales. The stock had closed at $90.44 the prior session.

Disc Medicine shares jumped 25.5% to $93 on October 17, 2025, after the FDA granted a Commissioner’s National Priority Voucher for its lead drug, bitopertin. The company filed a New Drug Application for bitopertin in late September; with the voucher, an approval decision could come as soon as late December. Several analysts raised their price targets sharply following the FDA news.